Pfizer’s revenue rose at an average annual rate of 25.6% from $41.7 billion in 2020 to $58.5 billion in 2023, while AbbVie’s revenue grew at an average rate of 6.5% from $45.8 billion to $54.3 ...

By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan ...

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

Pfizer's Coming for AbbVie's Market Share. ... (now that Humira is seeing competition from generics as a result of going over the patent cliff in the U.S. this year).

Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. It is unlikely that the Inflation Reduction Act will have ...

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has also been expanding its offerings into solid tumors. Its ...

The stock's fall snapped a three-day winning streak.

AbbVie’s CGRP pill Ubrelvy was approved in 2019 to treat migraine. It generated $680 million in sales last year for an increase of 23% on 2021. Lilly’s oral CGRP Reyvow was endorsed the same year.

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.